NET ASSET VALUE – 31 July 2026
NET ASSET VALUE – 31 July 2026
2026-08-04 08:00:00
On the 31 July 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,404 million and NAV per share was SEK 39.26. Return on NAV per share in the month was 0.3%.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Lipum | 100% | 348 | 4.01 | 10.2% |
| Prokarium | 50% | 286 | 3.30 | 8.4% |
| KAHR Medical | 34% | 205 | 2.37 | 6.0% |
| Empros Pharma | 79% | 204 | 2.36 | 6.0% |
| Atrogi | 44% | 197 | 2.27 | 5.8% |
| Bonsai Biotherapeutics | 100% | 158 | 1.82 | 4.6% |
| Xspray Pharma | 17% | 135 | 1.55 | 4.0% |
| Microbiotica | 10% | 128 | 1.48 | 3.8% |
| Mendus | 22% | 98 | 1.13 | 2.9% |
| Xintela | 60% | 96 | 1.11 | 2.8% |
| AnaCardio | 13% | 79 | 0.92 | 2.3% |
| Geneos Therapeutics | 12% | 68 | 0.79 | 2.0% |
| EpiEndo Pharmaceuticals | 9% | 54 | 0.63 | 1.6% |
| Vitara Biomedical | 11% | 54 | 0.62 | 1.6% |
| Buzzard Pharmaceuticals | 15% | 33 | 0.38 | 1.0% |
| Egetis Therapeutics | 1% | 29 | 0.34 | 0.9% |
| Amarna Therapeutics | 58% | 11 | 0.13 | 0.3% |
| Strike Pharma | 18% | 11 | 0.12 | 0.3% |
| Total | 2,196 | 25.33 | 64.5% | |
| Commercial Growth | ||||
| Symcel | 30% | 211 | 2.43 | 6.2% |
| NorthX Biologics | 61% | 202 | 2.33 | 5.9% |
| Chromafora | 28% | 137 | 1.59 | 4.0% |
| Nanologica | 50% | 72 | 0.83 | 2.1% |
| Frontier Biosolutions | 2% | 26 | 0.31 | 0.8% |
| Bohus Biotech | 45% | 22 | 0.26 | 0.6% |
| Total | 671 | 7.74 | 19.7% | |
| Assets related to Portfolio companies | 228 | 2.63 | 6.7% | |
| Other assets and liabilities | 309 | 3.56 | 9.1% | |
| Net Asset Value | 3,404 | 39.26 | 100.0% | |